PepGen Inc.
PEPG | NASDAQ
$2.84
-$0.01 (-0.35%)
At close: Sep 21, 2026, 4:00 PM ET
$2.82
-$0.02 (-0.69%)
Pre-market:
Sep 22, 2026, 7:58 AM ET
Company Profile
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
Key Executives
| Name | Position |
|---|---|
| James G. McArthur | President, Chief Executive Officer, Treasurer, Secretary & Director |
| Kasra Kasraian | Chief Technology Officer |
| Noel Donnelly | Chief Financial Officer |
| Emiko Bryant | Senior Vice President of HR & Administration |
| Gregory Song | Executive Director & Head of Biometrics |
| Hayley Parker | Senior Vice President of Global Regulatory Affairs & Quality |
| Joseph D. Vittiglio | Chief Business & Legal Officer and Secretary |
| Melissa Michaels | Executive Director & Head of Regulatory Affairs CMC |
| Michael Zhao | Vice President & Head of Biometrics |
| Pallavi Lonkar | Vice President & Head of Preclinical |
| Paul D. Streck | Executive Vice President and Head of Research & Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 06, 2026 | 8-K | Current Report |
| Aug 06, 2026 | 10-Q | Quarterly Report |
| Jun 22, 2026 | 4 | Filing |
| Jun 22, 2026 | 8-K | Current Report |
| Jun 22, 2026 | 4 | Filing |
| Jun 22, 2026 | 4 | Filing |
| Jun 22, 2026 | 4 | Filing |
| Jun 22, 2026 | 4 | Filing |
| Jun 22, 2026 | 4 | Filing |
| Jun 22, 2026 | 4 | Filing |
PepGen Inc.
| Country | United States |
| IPO Date | May 5, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 57 |
| CEO | James McArthur |
Contact Details
321 Harrison Avenue Boston,
Massachusetts 02118 United States
Stock Details
| Ticker Symbol | PEPG |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001835597 |
| CUSIP Number | 713317105 |
| ISIN Number | US7133171055 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove PEPG